Abacus Medicine Pharma Services has signed a partnership agreement with Mirum Pharmaceuticals Inc. for the commercialization of LIVMARLI (maralixibat) oral solution in the Nordic markets. Under the terms of the agreement, Mirum has appointed Abacus to exclusively promote, market, sell, distribute, and commercialize LIVMARLI in the territory of Denmark, Finland, Iceland, Norway, and Sweden.   LIVMARLI is an orally administered, ileal bile acid transporter (IBAT) inhibitor approved with orphan d...